Category: Industry News

We are proud to announce the appointment of Stephane Argivier as our new Chief Executive Officer, effective from 1^st September 2024. Stephane Argivier will lead the next stage in the company’s expansion and succeeds Dr. James Steggles, the company’s founder, who announces he will remain Chair of the Board.

The announcement follows recent company successes in which Logical Biological received prestigious accolades, including securing the 149^th spot in the “FT 1000: Europe’s Fastest Growing Companies” listing and a King’s Award for International Trade, recognising 5 years of impressive growth for Logical Biological.

Stephane Argivier, former CEO at MIP Discovery, recently renamed as Tozaro, and previously Managing Director at SCIPAC, now part of BBI Solutions; became Non-Executive Director and member of the Board at Logical Biological in 2021.

Stephane Argivier has a successful track record with over 25 years’ experience in growing critical reagent businesses for applications in ‘in-vitro’ diagnostics and Life Science tools. As Managing Director of SCIPAC, he transformed the company’s business model and offering, to achieve broad market adoption of customer centric products. SCIPAC was sold to the multinational BBI Solutions in 2010.

Stephane has also played a key role in shaping the Logical Biological strategy to date, which has underpinned its stellar growth.  As a successful Life Science business leader with depth of expertise in clinical biospecimens and the affinity diagnostic reagents market, Stephane is ideally suited to lead a smooth transition, scale the business and lead its ambitious expansion plans.

Biospecimen and manufactured bioreagents are critical for R&D, validation, manufacture and QC of diagnostic assays, and yet quality, sustainability and technical support can be a challenge to meet the ever-increasing standards required in ‘in vitro diagnostics’. Logical Biological aims to deliver an unmatched level of quality, expertise and technical understanding of customer applications to address these.

Dr. James Steggles, Chair of Logical Biological, said: “We are delighted that Stephane has agreed to become our new CEO. His leadership and expertise will drive Logical Biological forward in its mission to deliver a sustainable supply of critical material solutions to accelerate our customers diagnostic and therapeutic advancements’’

Stephane Argivier, incoming Chief Executive, said: “I joined Logical Biological as CEO because I could see the great potential in the company, knowing the value of deep expertise, quality and exceptional customer service to deliver critical and complex bioreagent solutions to the IVD market. In my 4 years with the business as a Board Director, I have been impressed by the quality of our people, know-how and the strength of our client relationships, which provide strong foundations on which to build in the years ahead. I believe we have an exciting future in front of us to expand the business and deliver value for our customers and shareholders.’’

We are proud to announce that Logical Biological has been honoured with the King’s Award for Enterprise. This prestigious award recognises Logical Biological’s excellence in International Trade for Outstanding Short-Term Growth in overseas sales over the last three years (2020-2022), which amounted to a more than one hundred and seventy per cent increase in international revenues during the period. This growth was achieved organically, amidst the challenging circumstances of the COVID-19 pandemic and is a mark of the company’s excellent reputation and unwavering commitment to providing high-quality biological samples to its diagnostic and therapeutic customers.

The King’s Awards for Enterprise, previously known as The Queen’s Awards for Enterprise, were renamed last year to reflect His Majesty The King’s desire to continue the legacy of HM Queen Elizabeth II’s by recognising outstanding UK businesses. The Award programme, now in its 58th year, is the most prestigious business award in the country. The awards celebrate the success of exciting and innovative businesses which are leading the way in one of four categories: Innovation, International Trade, Sustainable Development and Promoting Opportunity (through social mobility).

“We are delighted to receive the King’s Award for International Trade, which affirms our role as a leader in the global biospecimens market,” expressed Dr James Steggles, Managing Director of Logical Biological. “This award is a testament to the tireless efforts of our team and the trust our customers place in us as their supplier of choice for high-quality biospecimens. Our commitment to excellence not only propels our growth but also significantly furthers our mission to contribute to a healthier world.”

Over the three-year period, Logical Biological worked with a record number of customers, including many of the top 10 global leading companies in In Vitro Diagnostics (IVD) test manufacturing. It shipped products to twenty-four countries (including the USA, Germany, South Korea, Ireland, and Australia), and continues to expand its reach globally. The success of Logical Biological on a global scale can be attributed to its comprehensive range of biological samples and its commitment to quality, reliability, customer service, and responsiveness. The company’s deep understanding of the international scientific community’s needs, coupled with its focus on a customer-centric approach and strict quality control protocols, ensure superior product quality and customer satisfaction.

Lowri Cope, Commercial Director at Logical Biological, added, “We are immensely proud to be recognized for our outstanding growth in international trade. Our strong relationships within the global In Vitro Diagnostics (IVD) community form the foundation of our success. We are excited to continue this trajectory, expanding our partnerships and enhancing our role in diagnostics and therapeutic research and development.”

This recognition is not just an award but a reflection of Logical Biological’s dedication to impacting the global healthcare landscape positively.

We’re excited to share a milestone in our journey at Logical Biological. Our relentless dedication to customer centricity and unwavering commitment to quality has led to us securing 149th spot in the prestigious “FT 1000: Europe’s Fastest Growing Companies” listing, a recognition that fills us with immense pride and joy.

The “FT 1000” list, created in collaboration with Statista, shines a spotlight on the European companies that have shown extraordinary growth. The ranking is determined by analysing the compound annual growth rate (CAGR) in revenue from 2019 to 2022. In a list that is dominated by IT, Software, Construction and Energy/ Utility companies, Logical Biological is proud to be leading the way for science.

Our Managing Director, Dr James Steggles, reflects on this achievement with gratitude, attributing it to the hard work of our team and the trust our customers place in us. “This recognition validates our team’s dedication and the close relationships we’ve built with our partners who share our vision of creating a healthier world. It’s their trust in us as a provider of high-quality biospecimens that has propelled our growth.”

Our position in the list is not just a number—it’s a narrative of our dedication to delivering excellence. Our expansive array of biological samples, combined with our focus on responsiveness, reliability, and quality, illustrates our commitment to the scientific community. We strive to understand and meet their needs ensuring that our products and services exceed expectations and maintain the highest quality standards.

Lowri Cope, Commercial Director, echoes this sentiment, expressing enthusiasm for our future endeavours. “Being acknowledged as one of Europe’s fastest-growing companies is a milestone that fuels our ambition. We look forward to building on this success and forging new partnerships in the advancement of scientific research and healthcare.”

As we celebrate this achievement, we’re not just looking back at our successes—we’re looking forward to the opportunities that lie ahead. Our vision is clear. Join us as we continue to forge ahead, solidifying our role as your trusted partner for biospecimens.